EP Patent

EP2767285B1 — TABLET COMPRISING 7-[4-(4-BENZO[b]THIOPHEN-4-YL-PIPERAZIN-1-YL) BUTOXY]-1H-QUINOLIN-2-ONE OR A SALT THEREOF

Assigned to Otsuka Pharmaceutical Co Ltd · Expires 2019-11-27 · 6y expired

What this patent protects

Patent listed against Rexulti.

Drugs covered by this patent

Patent Metadata

Patent number
EP2767285B1
Jurisdiction
EP
Classification
—
Expires
2019-11-27
Drug substance claim
No
Drug product claim
No
Assignee
Otsuka Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.